B of A Securities Reiterates Buy Rating on Jazz Pharmaceuticals
B of A Securities maintains a buy rating for Jazz Pharmaceuticals, setting a $307 price target, a 33.15% upside from the current price.
Key Points
- B of A Securities reiterated its buy rating on Jazz Pharmaceuticals with a price target of $307.
- B of A Securities's $307 price target implies 33.15% upside from Jazz Pharmaceuticals plc's ($JAZZ) current $230.56 share price.
- Jazz Pharmaceuticals, trading at $230.56, has a market cap of $14.48 billion and a forward P/E of 9.0.
- Insiders at Jazz Pharmaceuticals made several planned sales, including EVP Neena Patil selling 1,200 shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
B of A Securities reiterated its buy rating on Jazz Pharmaceuticals (NasdaqGS: JAZZ) on June 10, 2026, setting a price target of $307. Analyst Jason Gerberry expressed continued confidence in the stock, which recently traded around $230.56.
Jazz Pharmaceuticals plc Stock Down 5.7%
Shares of Jazz Pharmaceuticals are currently trading at $230.56 on the NasdaqGS. The company has a market cap of approximately $14.48 billion and a forward P/E ratio of about 9.0. Jazz's stock has a 52-week range between $105.00 and $243.32, with a 50-day moving average of $217.29 and a 200-day moving average of $173.04. The company maintains a current ratio of 2.04 and a quick ratio of 1.65, with a debt-to-equity ratio of 119.52.
Recent Earnings
In its most recent financial report, Jazz Pharmaceuticals reported revenue of approximately $4.44 billion, with a revenue growth rate of 19.1%. The company's net margin stood at 0.66%, while return on equity was 0.68%. Jazz is expected to announce its next earnings on May 5, 2026.
Insider Buying and Selling at Jazz Pharmaceuticals plc
Several insiders at Jazz Pharmaceuticals have made planned sales recently. On June 10, 2026, Neena Patil, EVP & Chief Legal Officer, sold 1,200 shares at an average price of $231.83. Earlier, on June 1, 2026, Bruce Cozadd sold 6,000 shares at $235.12 under a planned transaction.
Analysts Set New Price Targets
On June 10, 2026, B of A Securities maintained its buy rating on Jazz Pharmaceuticals with a price target of $307. Barclays also maintained a buy rating with a $253 target on May 27, 2026. UBS upgraded Jazz to a buy with a $307 target on May 19, 2026. Overall, the consensus among 19 analysts is a buy rating, with an average price target of $255.95.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, headquartered in Dublin, Ireland, is a global biopharmaceutical company. It focuses on developing and marketing pharmaceutical products for various medical conditions, including sleep disorders and cancer. Led by CEO Renee D. Gala, Jazz Pharmaceuticals employs around 2,890 people. Its key products include Xywav, Epidiolex, and Rylaze, among others.
Bottom Line
B of A Securities' reiteration of its buy rating on Jazz Pharmaceuticals underscores continued optimism for the company's future performance. With a solid market position and a diverse product portfolio, Jazz Pharmaceuticals remains a significant player in the biotechnology sector. Investors should note that analyst ratings are one of many factors to consider, and this 13F filing reflects data as of the reporting period.
Get Jazz Pharmaceuticals plc alerts
New 13F filings, insider trades, and analyst moves on $JAZZ, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.